Interpace Biosciences stock: price, dividend and review in 2026

Interpace Biosciences stock represents an American molecular-diagnostics laboratory specialised in thyroid and pancreatic cancers: its genetic tests guide the surgical decisions of thousands of patients, a niche back to profitability.

This sheet brings together verified information on Interpace: profile, last three fiscal years’ results, strengths and risks, then the precautions before considering a purchase from France.

Interpace stock price

Interpace trades over the counter (OTC) under the symbol IDXG, in dollars: liquidity there is lower than on an organised exchange — check the stock’s availability with your broker. Our page on the New York Stock Exchange presents the organised American markets for comparison.

Interpace stock profile

CompanyInterpace Biosciences, Inc.
MarketOTC (American over-the-counter market) — currency USD (checked on 08/11/2026)
Ticker / SymbolIDXG (OTC)
ISINUS46062X4025
HeadquartersParsippany, New Jersey (United States)
SectorHealthcare — molecular diagnostics
Quotation currencyUS dollar (USD)
Fiscal year end31 December
PEA eligibilityNo (American OTC stock: ordinary securities account and availability check with the broker)

Interpace presentation: the tests that avoid surgery

Thyroid and pancreas: two leading tests

ThyGeNEXT and ThyraMIR assess thyroid nodules before any surgery: when the test rules out cancer, the patient avoids an unnecessary operation. PancraGEN applies the same logic to pancreatic cysts. The model relies on volumes sent by American endocrinologists and gastroenterologists.

Revenue stabilises around $39 million in 2025 ($46.9 million in 2024). The 2025 net income of $24.6 million is supported by non-recurring tax items — current operating profit remains near break-even.

Micro-cap, no dividend

Net cash has become marginal but positive (around $1.3 million) after the clean-up.

No dividend is paid: resources finance commercial development.

Interpace results and financial data

Interpace stabilises its revenue and shows a profit supported by tax items.

IndicatorFY 2023FY 2024FY 2025One-year change
Revenue$40.0m$46.9m$38.7m-17.5%
Net income (group share)$1.9m$6.2m$24.6m+293.9%
Net cash (+) / net debt (−)-$7.7m-$4.4m$1.3m—

Amounts in millions (m) or billions (bn) of US dollars. Source: S&P Global Market Intelligence via StockAnalysis, company annual reports; data consulted on 23/10/2026.

In 2025, revenue stands at $39 million, down 17%. The net income of $24.6 million includes non-recurring tax items.

Net cash is marginal but positive. No dividend is paid.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Interpace stock dividend

Interpace pays no dividend.

The expected return therefore comes solely from the price’s evolution.

Should You Buy Interpace Stock in 2026?

Interpace suits speculative investors comfortable with OTC micro-caps. Before any position, remember that the daily traded value counts in tens of thousands of dollars only: small orders are a must, and exiting can prove trickier than entering on this type of stock.

Strengths

  • Reference tests on thyroid nodules and pancreatic cysts.
  • Return to positive net cash.
  • Net profit displayed over two fiscal years.

Risks to watch

  • OTC-quoted micro-capitalisation, low liquidity.
  • Profit dependent on non-recurring items.
  • Pricing pressure from American insurers.

The file lends itself to a minimal speculative pocket, tracked through test volumes.

Fundamental and technical analysis of Interpace

Fundamental analysis

To follow: test volumes by product, insurer collections and cash.

Technical analysis

The OTC IDXG chart reflects the stock’s very speculative nature.

How to buy Interpace stock?

The Interpace stock trades in American over-the-counter trading, in dollars — check its availability with your broker.

  1. Choose a broker giving access to American OTC markets: not all cover them. Compare brokerage and currency fees in our selection of the best stock brokers.
  2. Open an ordinary securities account (the PEA is not available for this non-EU foreign stock), then have your identity verified.
  3. Fund the account by transfer, taking currency-conversion fees into account.
  4. Place the order on the IDXG symbol, with a limit — on an illiquid OTC stock, market orders are to be banned.

Trading hours and conditions

American markets trade from 9:30 am to 4:00 pm New York time, i.e. generally 3:30 pm to 10:00 pm in Paris. US stocks can be bought per unit, and some brokers even offer fractional shares. Fill in the W-8BEN form at account opening.

Taxation and currency (France)

Thanks to the W-8BEN form, the US withholding on dividends is reduced to 15%, creditable against French tax. Performance in euros also depends on the dollar’s evolution. (Non-French readers: check your own jurisdiction’s rules.)

Frequently asked questions about Interpace stock

On which exchange is Interpace stock listed?

On the OTC market (American over-the-counter), under the symbol IDXG, in dollars.

Is Interpace eligible for the PEA?

No. The stock is held, if the broker offers it, in an ordinary securities account.

Does Interpace pay a dividend?

No dividend is paid.

What is Interpace’s symbol?

IDXG on the American OTC market.

What does Interpace Biosciences do?

Genetic tests (ThyGeNEXT, PancraGEN) that guide the surgical decision in thyroid and pancreatic cancers.

Disclaimer: this content is informational and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not indicative of future performance.

Suivez-nous sur Telegram